Details of the Drug
General Information of Drug (ID: DMCUE25)
Drug Name |
1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
183500-36-9; CHEMBL599601; 4-(5-HYDROXYMETHYLIMIDAZOL-1-YLMETHYL)BENZONITRILE; 1-(4-cyanobenzyl)-5-hydroxymethylimidazole; 1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole; SCHEMBL3630524; CTK4D8500; DTXSID40436662; ACFSBQWDVYWNRT-UHFFFAOYSA-N; ZINC45368822; BDBM50307240; ACM183500369; KB-238618; 1-(4-Cyanobenzyl)-5-Hydroxymethyl-imidazole; 1-(4-Cyanobenzyl)-5-(hydroxymethyl)imidazole; 1-(4-cyanobenzyl)-5-(hydroxymethyl) imidazole; 1-(4-cyanobenzyl)-5-(hydroxymethyl)-imidazole; 3-(4-cyanobenzyl)-3H-imidazol-4-ylmethyl alcohol
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 213.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||